Efficacy of Drug-Coated Balloon Approaches for de novo Coronary Artery Diseases: A Bayesian Network Meta-Analysis

Peng-Yu Zhong, Ying Ma, Yao-Sheng Shang, Ying Niu, Nan Bai, Zhi-Lu Wang, Peng-Yu Zhong, Ying Ma, Yao-Sheng Shang, Ying Niu, Nan Bai, Zhi-Lu Wang

Abstract

Background and objective: The de novo coronary lesions are the most common form of coronary artery disease, and stent implantation still is the main therapeutic strategy. This network meta-analysis aims to evaluate the efficacy of drug-coated balloons only (DCB only) and DCB combined with bare-metal stents (DCB+BMS) strategies vs. drug-eluting stents (DES) and BMS approaches in coronary artery de novo lesion.

Method: PubMed, EMBASE, and Cochrane Library databases were retrieved to include the relevant randomized controlled trials that compared DCB approaches and stents implantation in patients with de novo coronary artery diseases. The primary outcome was major adverse cardiac events (MACE). The clinical outcomes included target lesion revascularization (TLR), all-cause death, and myocardial infarction. The angiographic outcomes consisted of in-segment late lumen loss (LLL) and binary restenosis. The odds ratio (OR) and 95% confidence intervals (95% CIs) for dichotomous data, and weighted mean differences for continuous data were calculated in the Bayesian network frame.

Result: A total of 26 randomized controlled trials and 4,664 patients were included in this study. The DCB-only strategy was comparable with the efficacy of MACE, clinical outcomes, and binary restenosis compared with DES. In addition, this strategy can significantly reduce the in-segment LLL compared with the first-generation (MD -0.29, -0.49 to -0.12) and the second-generation DES (MD -0.15, -0.27 to -0.026). However, subgroup analysis suggested that DCB only was associated with higher in-segment LLL than DES (MD 0.33, 0.14 to 0.51) in patients with acute coronary syndrome. Compared with DES, the DCB+BMS strategy had a similar incidence of myocardial infarction and all-cause death, but a higher incidence of MACE, TLR, and angiographic outcomes. In addition, DCB+BMS was associated with a similar incidence of myocardial infarction and all-cause death than BMS, with a lower incidence of MACE, TLR, and angiographic outcomes.

Conclusion: The DCB only is associated with similar efficacy and lower risk of LLL compared with DES. In addition, the DCB+BMS strategy is superior to BMS alone but inferior to DES (PROSPERO, CRD 42021257567).

Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/#recordDetails.

Keywords: de novo coronary artery diseases; drug-coated balloon; drug-eluting stents; network meta-analysis; percutaneous coronary intervention.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Zhong, Ma, Shang, Niu, Bai and Wang.

Figures

Figure 1
Figure 1
Flow diagram of literature search.
Figure 2
Figure 2
Network evidence plot.
Figure 3
Figure 3
Forest plots of entire cohort compared with first-generation DES. (A) MACE; (B) TLR; (C) all-cause death; (D) myocardial infraction; (E) LLL; (F) BR.
Figure 4
Figure 4
Forest plots of entire cohort compared with second-generation DES. (A) MACE; (B) TLR; (C) all-cause death; (D) myocardial infraction; (E) LLL; (F) BR.
Figure 5
Figure 5
Rankograms on broken line graph from MACE and LLL. (A) MACE; (B) LLL. The 1–5 on X axial refers to the rank from the best to the worst. The number on y axial refers to the probability of rank.

References

    1. Dong Y, Chen H, Gao J, Liu Y, Li J, Wang J. Molecular machinery and interplay of apoptosis and autophagy in coronary heart disease. J Mol Cell Cardiol. (2019) 136:27–41. 10.1016/j.yjmcc.2019.09.001
    1. Lee SY, Hong MK, Shin DH, Kim JS, Kim BK, Ko YG, et al. . Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors. Clin Res Cardiol. (2017) 106:165–73. 10.1007/s00392-016-1035-4
    1. Varenhorst C, Lindholm M, Sarno G, Olivecrona G, Jensen U, Nilsson J, et al. . Stent thrombosis rates the first year and beyond with new- and old-generation drug-eluting stents compared to bare metal stents. Clin Res Cardiol. (2018) 107:816–23. 10.1007/s00392-018-1252-0
    1. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. . 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. (2018) 39:213–60. 10.1093/eurheartj/ehx638
    1. Baan J Jr, Claessen BE, Dijk KB, Vendrik J, van der Schaaf RJ, Meuwissen M, et al. . A randomized comparison of paclitaxel-eluting balloon versus everolimus-eluting stent for the treatment of any in-stent restenosis: The DARE trial. JACC Cardiovasc Interv. (2018) 11:275–83. 10.1016/j.jcin.2017.10.024
    1. Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V, et al. . 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. (2014) 46:517–92. 10.1093/eurheartj/ehu278
    1. Cui K, Lyu S, Song X, Yuan F, Xu F, Zhang M, et al. . Drug-eluting balloon versus bare-mental stent and drug-eluting stent for de novo coronary artery disease: a systematic review and meta-analysis of 14 randomized controlled trials. PLoS ONE. (2017) 12:e0176365. 10.1371/journal.pone.0176365
    1. Cortese B, Micheli A, Picchi A, Coppolaro A, Bandinelli L, Severi S, et al. . Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart. (2010) 96:1291–6. 10.1136/hrt.2010.195057
    1. Latib A, Colombo A, Castriota F, Micari A, Cremonesi A, De Felice F, et al. . A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study. J Am Coll Cardiol. (2012) 60:2473–80. 10.1016/j.jacc.2012.09.020
    1. Siontis GC, Piccolo R, Praz F, Valgimigli M, Räber L, Mavridis D, et al. . Percutaneous coronary interventions for the treatment of stenoses in small coronary arteries: a network meta-analysis. JACC Cardiovasc Interv. (2016) 9:1324–34. 10.1016/j.jcin.2016.03.025
    1. Jeger RV, Farah A, Ohlow MA, Mangner N, Möbius-Winkler S, Leibundgut G, et al. . Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet. (2018) 392:849–56. 10.2139/ssrn.3210892
    1. Rissanen TT, Uskela S, Eränen J, Mäntylä P, Olli A, Romppanen H, et al. . Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial. Lancet. (2019) 394:230–9. 10.1016/S0140-6736(19)31126-2
    1. Vos NS, Fagel ND, Amoroso G, Herrman JR, Patterson MS, Piers LH, et al. . Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction: The REVELATION randomized trial. JACC Cardiovasc Interv. (2019) 12:1691–9. 10.1016/j.jcin.2019.04.016
    1. Stella PR, Belkacemi A, Dubois C, Nathoe H, Dens J, Naber C, et al. . A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial. Catheter Cardiovasc Interv. (2012) 80:1138–46. 10.1002/ccd.23499
    1. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. (2021) 18:e1003583. 10.1371/journal.pmed.1003583
    1. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. . The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. (2015) 162:777–84. 10.7326/M14-2385
    1. Puhan MA, Schünemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. . GRADE working group. A GRADE working group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. (2014) 349:g5630. 10.1136/bmj.g5630
    1. Salanti G, Del Giovane C, Chaimani A, Caldwell DM, Higgins JP. Evaluating the quality of evidence from a network meta-analysis. PLoS ONE. (2014) 9:e99682. 10.1371/journal.pone.0099682
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. (2003) 327:557–60. 10.1136/bmj.327.7414.557
    1. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. (2011) 64:163–71. 10.1016/j.jclinepi.2010.03.016
    1. Zhang WJ, Qiao X, Liang XY, Li Y, Yang RR, Wang ZL. Efficacy and safety of short-term 1-3 months versus standard 12 months dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials. Platelets. (2021) 32:582–90. 10.1080/09537104.2020.1786039
    1. Nayak AK, Kawamura A, Nesto RW, Davis G, Jarbeau J, Pyne CT, et al. . Myocardial infarction as a presentation of clinical in-stent restenosis. Circ J. (2006) 70:1026–9. 10.1253/circj.70.1026
    1. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, et al. . Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. (2009) 119:3198–206. 10.1161/CIRCULATIONAHA.108.826479
    1. Jensen LO, Maeng M, Kaltoft A, Thayssen P, Hansen HH, Bottcher M, et al. . Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol. (2007) 50:463–70. 10.1016/j.jacc.2007.06.002
    1. Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. (2018) 7:e011245. 10.1161/JAHA.118.011245
    1. Dan K, Garcia-Garcia HM, Kolm P, Windecker S, Saito S, Kandzari DE, et al. . Comparison of ultrathin, bioresorbable-polymer sirolimus-eluting stents and thin, durable-polymer everolimus-eluting stents in calcified or small vessel lesions. Circ Cardiovasc Interv. (2020) 13:e009189. 10.1161/CIRCINTERVENTIONS.120.009189
    1. Kim BK, Hong SJ, Cho YH, Yun KH, Kim YH, Suh Y, et al. . Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. (2020) 323:2407–16. 10.1001/jama.2020.7580
    1. Hamilos M, Sarma J, Ostojic M, Cuisset T, Sarno G, Melikian N, et al. . Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses. Circ Cardiovasc Interv. (2008) 1:193–200. 10.1161/CIRCINTERVENTIONS.108.797928
    1. Byrne RA, Sarafoff N, Kastrati A, Schömig A, et al. . Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment. Drug Saf. (2009) 32:749–70. 10.2165/11316500-000000000-00000
    1. Kleber FX, Rittger H, Bonaventura K, Zeymer U, Wöhrle J, Jeger R, et al. . Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group. Clin Res Cardiol. (2013) 102:785–97. 10.1007/s00392-013-0609-7
    1. Wańha W, Bil J, Januszek R, Gilis-Malinowska N, Figatowski T, Milewski M, et al. . Long-term outcomes following drug-eluting balloons versus thin-strut drug-eluting stents for treatment of in-stent restenosis (DEB-dragon-registry). Circ Cardiovasc Interv. (2021) 14:e010868. 10.1161/CIRCINTERVENTIONS.121.010868
    1. Herdeg C, Göhring-Frischholz K, Haase KK, Geisler T, Zürn C, Hartmann U, et al. . Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation. Circ Cardiovasc Interv. (2009) 2:294–301. 10.1161/CIRCINTERVENTIONS.108.827865.108.827865
    1. McKavanagh P, Zawadowski G, Ahmed N, Kutryk M. The evolution of coronary stents. Expert Rev Cardiovasc Ther. (2018) 16:219–28. 10.1080/14779072.2018.1435274
    1. Elgendy IY, Gad MM, Elgendy AY, Mahmoud A, Mahmoud AN, Cuesta J, et al. . Clinical and angiographic outcomes with drug-coated balloons for de novo coronary lesions: a meta-analysis of randomized clinical trials. J Am Heart Assoc. (2020) 9:e016224. 10.1161/JAHA.120.016224
    1. Jeger RV, Eccleshall S, Wan Ahmad WA, Ge J, Poerner TC, Shin ES, et al. . Drug-Coated balloons for coronary artery disease: third report of the international DCB consensus group. JACC Cardiovasc Interv. (2020) 13:1391–1402. 10.1016/j.jcin.2020.02.043
    1. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, et al. . Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. (2015) 65:2496–507. 10.1016/j.jacc.2015.04.017
    1. Mehran R, Chandrasekhar J, Urban P, Lang IM, Windhoevel U, Spaulding C, et al. . LEADERS FREE investigators. sex-based outcomes in patients with a high bleeding risk after percutaneous coronary intervention and 1-month dual antiplatelet therapy: a secondary analysis of the LEADERS FREE randomized clinical trial. JAMA Cardiol. (2020) 5:939–47. 10.1001/jamacardio.2020.0285
    1. Poerner TC, Otto S, Gassdorf J, Nitsche K, Janiak F, Scheller B, et al. . Stent coverage and neointimal proliferation in bare metal stents postdilated with a Paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up. Circ Cardiovasc Interv. (2014) 7:760–7. 10.1161/CIRCINTERVENTIONS.113.001146
    1. Burzotta F, Brancati MF, Trani C, Pirozzolo G, De Maria G, Leone AM, et al. . Impact of drug-eluting balloon (pre- or post-) dilation on neointima formation in de novo lesions treated by bare-metal stent: the IN-PACT CORO trial. Heart Vessels. (2016) 31:677–86. 10.1007/s00380-015-0671-3

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir